|
Determine whether long term growth hormone replacement therapy (Humatrope®) administered in clinical practice to adults with growth hormone deficiency is associated with an increased or decreased incidence of clinically significant adverse events.
Who is Eligible to Participate?
•· Adults with growth hormone deficiency as defined by the approved package insert for Humatrope (for each country)
•· Patients who have achieved final adult height
•· Patients may be on growth hormone replacement treatment - must the treatment must be Humatrope
•· Patients must have a diagnosed growth hormone deficiency but do not need to be on hormone replacement treatment
What is Involved?
No procedures are required beyond those performed as part of clinical practice (standard of care)
Visit 1
•· Detailed medical history
•· Growth hormone stimulation test if indicated
Flexible follow-up visit schedule
•· 1-2 study visits per year (no defined interval)
|
